AVCT Share Price Performance
Recent AVCT News & Updates
No updates
Avacta Group Plc Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.076
- Gross Margin
- 100.00%
- Net Profit Margin
- -26,041.59%
- Debt/Equity Ratio
- 234.7%
Avacta Group Plc Competitors
About AVCT
- Founded
- 2003
- Employees
- 151
- CEO
- WebsiteView website
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.
U.K. Market Performance
- 7 Days: 1.1%
- 3 Months: 7.3%
- 1 Year: 7.4%
- Year to Date: 7.7%
Over the last 7 days, the market has risen 1.1%, driven by gains of 5.3% in the Materials sector. The market is up 7.4% over the last 12 months. Earnings are forecast to grow by 15% annually. Market details ›
The tide is turning for UK & European markets. Index ETFs won’t cut it since sector spreads are massive. Picking the right companies matters now more than ever.
Continue readingLast Week
